As a result of studies that show an inferior prognosis for AIB1-high tumors in endocrine-treated estrogen receptor-positive breast cancer cohorts [5, 7, 8], AIB1 has previously been suggested to be of importance for endocrine treatment resistance. Here, ESR1 is linked to breast carcinoma.